Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: J Allergy Clin Immunol. 2014 Jan 22;133(5):1356–136514. doi: 10.1016/j.jaci.2013.11.030

Figure 2. 25OHD3 driven inhibition of IgE-mediated activation functions via mast cell-CYP27B1 catalytic activity.

Figure 2

A) CYP27B1 and β-actin protein expression in WT and VDR−/− BMCMCs cultured for 3 or 8 h with 25OHD3 at indicated concentrations or vehicle (EtOH). (B) WT, VDR−/−, or CYP27B1−/− BMCMC production of 1α,25(OH)2D3 (1α25D3) incubated with 25OHD3 for 6 h. (C to F) WT and CYP27B1−/− BMCMCs pre-treated with 25OHD3 24 h prior to IgE + DNP-HSA stimulation and release of (C) histamine (30 min), (D) Cys-LT (30 min), (E) TNF (6 h), and (F) IL-6 (6 h) into supernatants. Data: 3 to 4 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001 for the indicated comparisons.